Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects
JT Hartmann, M Haap, HG Kopp… - Current drug …, 2009 - ingentaconnect.com
Tyrosine kinase inhibitors (TKI) are effective in the targeted treatment of various
malignancies. Imatinib was the first to be introduced into clinical oncology, and it was …
malignancies. Imatinib was the first to be introduced into clinical oncology, and it was …
Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome—Positive acute lymphoblastic leukemia
M Steinberg - Clinical therapeutics, 2007 - Elsevier
Background: The Philadelphia chromosome is formed from a translocation of genetic
material involving human chromosomes 9 and 22. The resulting gene product, BCR-ABL …
material involving human chromosomes 9 and 22. The resulting gene product, BCR-ABL …
[图书][B] WHO classification of tumours of haematopoietic and lymphoid tissues
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is the second
volume of the 4th Edition of the WHO series on histological and genetic typing of human …
volume of the 4th Edition of the WHO series on histological and genetic typing of human …
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
H Kantarjian, M Talpaz, S O'Brien, G Garcia-Manero… - Blood, 2004 - ashpublications.org
Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …
Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
HM Kantarjian, M Talpaz, S O'Brien, D Jones, F Giles… - Blood, 2006 - ashpublications.org
A survival benefit for imatinib mesylate versus interferon-α therapy could not be
demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph) …
demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph) …
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia …
N Takahashi, T Tauchi, K Kitamura, K Miyamura… - International journal of …, 2018 - Springer
The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study
The purpose of this study was to analyze medical late effects among patients with chronic
myeloid leukemia (CML) treated with hematopoietic cell transplantation (HCT). Subjects …
myeloid leukemia (CML) treated with hematopoietic cell transplantation (HCT). Subjects …
[HTML][HTML] HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p/USP6/GLS1 axis
X Chen, Y Chen, M Zhang, H Cheng, H Mai, M Yi… - Cell Death & …, 2022 - nature.com
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with increasing incidence
worldwide. Growing evidence suggests that ubiquitin-specific proteases (USPs) play a role …
worldwide. Growing evidence suggests that ubiquitin-specific proteases (USPs) play a role …
[HTML][HTML] MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a severe problem throughout the world and requires
identification of novel targets for its treatment. This multifactorial disease accounts for about …
identification of novel targets for its treatment. This multifactorial disease accounts for about …